[1] |
HUANG Kaige, XU Qinhua, WANG Wei.
Interaction effect and predictive efficacy of blood glucose and blood calcium on the prognosis of patients with acute severe pancreatitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1227-1234.
|
[2] |
ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi.
Interactions and clinical significance of gut microbiota and levothyroxine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
|
[3] |
MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu.
Correlation between 25(OH)D and metabolically related fatty liver in T2DM population
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
|
[4] |
WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong.
Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
|
[5] |
ZHANG Qiang, ZHENG Huajun, LI Quan.
Research progress on the treatment of autism spectrum disorders based on gut microbiota intervention
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 475-480.
|
[6] |
DUAN Ruixiao, ZHAO Yifan, YE Yongjuan, LIU Min, LI Qiang, ZHOU Yongning.
Mechanism of action of bile acid metabolism in regulating inflammatory bowel disease and the research and development of drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1171-1181.
|
[7] |
YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong.
Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
|
[8] |
MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling.
Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
|
[9] |
LU Yapeng, LIU Yang, HAO Wei, ZHONG Hailian, XIE Jianqin, LIU Jieting, WANG Yingbin.
Research progress on the role of pyroptosis in intestinal ischemia-reperfusion injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1437-1443.
|
[10] |
LIU Wenjing, WU Zhitao, PAN Guoyu.
Early dectection and prediction hepatotoxic risk in vitro
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 923-930.
|
[11] |
WU Yi, FANG Fang, CHEN Ying, Fan Junwei.
Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639.
|
[12] |
SONG Ruzheng, PENG Ying, WANG Guangji, SUN Jianguo.
Commonly used quantitative proteomics research techniques and their application in the study of pathogenesis of liver-derived diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 570-578.
|
[13] |
XU Lina, LI Yue, PENG Jinyong.
microRNA and drug-induced liver injury
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 803-809.
|
[14] |
YAN Yu, LIU Kang, LIAN Wenwen, ZHANG Zhen, HE Jun.
Research progress on roles of gut microbiota in cardiovascular disease and treatment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 829-834.
|
[15] |
LI Guiming,LI Yan,CHEN Li.
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 87-93.
|